Dyne Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DYN Nasdaq 2836 www.dyne-tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyne Therapeutics, Inc.

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Mar 12th, 2025 7:05 pm
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Mar 12th, 2025 5:12 pm
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - Mar 11th, 2025 11:30 am
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans? - Feb 28th, 2025 11:46 am
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Feb 27th, 2025 12:30 pm
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - Feb 14th, 2025 9:05 pm
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) - Feb 13th, 2025 2:35 pm
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Feb 6th, 2025 2:39 pm
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 3rd, 2025 12:30 pm
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Feb 3rd, 2025 9:09 am
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Jan 31st, 2025 1:03 pm
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround - Jan 28th, 2025 2:35 pm
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 - Jan 21st, 2025 12:30 pm
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall - Jan 10th, 2025 3:49 pm
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 - Jan 10th, 2025 11:30 am
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Jan 9th, 2025 12:30 pm
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Jan 8th, 2025 9:05 pm
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Nov 22nd, 2024 11:43 am
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 12th, 2024 12:30 pm
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases - Oct 9th, 2024 11:30 am